Board of Directors' Explanation on the Transaction Constituting a Major Asset Restructuring

Lideman Co., Ltd.·June 12, 2026·1 page

✨ AI Summary

Beijing Lideman Biochemical Co., Ltd. proposes to acquire 61.50% of Beijing Sian Ruixiang Bio-products Co., Ltd. for cash. The board has reviewed the transaction and concluded it constitutes a major asset restructuring according to relevant regulations. Financial data from year-end 2025 is used for the assessment.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Beijing Lideman Biochemical Co., Ltd.

Board of Directors' Explanation on the Transaction Constituting a Major Asset Restructuring

Beijing Lideman Biochemical Co., Ltd. (hereinafter referred to as the "Company" or "Listed Company") proposes to acquire 235,040,700 shares of Beijing Sian Ruixiang Bio-products Co., Ltd. (hereinafter referred to as "Sian Ruixiang") held by Hainan Baimai Investment Co., Ltd., Hainan Sian Ruixiang Baijiahui Technology Development Co., Ltd., and Nanjing Baijiarui Enterprise Management Consulting Partnership (Limited Partnership) through cash payment, representing 61.50% of the issued share capital of Sian Ruixiang (hereinafter referred to as the "Transaction").

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.